WEE1 and neoplasm: We show that 4T1ch9 tumour immunogenicity and tumour immune microenvironment remained unaltered in response to combined PARP and WEE1 inhibitor treatment (Supplementary Fig. 2b) suggesting that the anti-tumour efficacy in the 4T1ch9 metastatic model as seen in Fig. 2a might be largely independent of the immune system.